CMMB
Chemomab Therapeutics Ltd.
$1.81
+2.26%
$13.0M
No data for this timeframe.
Vol
Market Cap$13.0M
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$6.2K
Inst. Activity0 buys / 1 sells
Insider Activity1B / 0S
Insider Net $$10.0K
SEC Reports4
Press Releases1
Recent Activity
Jun 2, 2026
SEC
Chemomab Therapeutics appointed Gwen Melincoff as a new independent director and chair of the nominating and governance
6-K — Impact 2/10
May 29, 2026
Insider
Mor George Adi sold 31,712 shares
Chief Executive Officer @ $0.00 ($0.00)
May 29, 2026
Insider
Mor George Adi bought 4,878 shares
Chief Executive Officer @ $2.05 ($10.0K)
May 14, 2026
SEC
Chemomab reported Q1 2026 net loss of $1.8M ($0.003/share) vs $3.3M in Q1 2025, with cash burn reduced to $2.4M. The com
PRESS-RELEASE — Impact 4/10
May 14, 2026
SEC
Chemomab Therapeutics reported Q1 2026 financial results, with net loss narrowing to $1.8M from $3.3M YoY on lower R&D s
6-K — Impact 5/10
Inst.
MORGAN STANLEY — NEAR_EXIT
3,775 shares ($6.2K)
Inst.
MORGAN STANLEY — NEW
90,065 shares ($236.9K)
May 14, 2026
earnings
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
Chemomab announced financial and operating results for the first quarter and provided a corporate up
Price Targets
Historical data — last covering-analyst action Aug 2025. No current recommendation available.
$15.00 (Aug 2025)
Current $1.73
Low $5.00
Median $15.00
High $25.00
2 analysts
$5.00
$25.00
Analyst Ratings
3Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 27, 2025 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| May 16, 2025 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| Feb 20, 2025 | Maxim Group | MAINTAIN | Buy → Buy |
| Nov 15, 2024 | Oppenheimer | REITERATE | Outperform → Outperform |
| May 13, 2024 | Maxim Group | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $-0.02 | $-0.02 — $-0.02 | -11% YoY | 1 |
| Next FY | $-0.03 | $-0.03 — $-0.03 | -50% YoY | 1 |
Latest Reports
NEUTRAL
6-K
2/10
Chemomab Therapeutics appointed Gwen Melincoff as a new independent director and chair of the nominating and governance
Jun 2, 2026
NEUTRAL
PRESS-RELEASE
4/10
Chemomab reported Q1 2026 net loss of $1.8M ($0.003/share) vs $3.3M in Q1 2025, with cash burn reduced to $2.4M. The com
May 14, 2026
BULLISH
Press
8/10
Chemomab Therapeutics reported its full-year and Q4 2025 financial results, highlighted by a successful FDA End-of-Phase
Mar 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $6.2K | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 29, 2026 | Mor George | J | $0.00 |
| May 29, 2026 | Mor George | BUY | $10.0K |
1 institutional holders with $6.2K total value (3,775 shares) as of 2025-Q4. Top holders: MORGAN. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 3,775 | $6.2K | 100.0% | NEAR_EXIT -95.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | NEAR_EXIT | 90,065 | 3,775 | -95.8% | $6.2K | 2025-Q4 |
| MORGAN STANLEY | NEW | — | 90,065 | — | $236.9K | 2025-Q3 |
1 unique insiders with 1 transactions. Net insider value: $10.0K ($10.0K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 29, 2026 | Mor George Adi | Chief Executive Officer | J | 31,712 | $0.00 | $0.00 |
| May 29, 2026 | Mor George Adi | Chief Executive Officer | BUY | 4,878 | $2.05 | $10.0K |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 3.3/10.
NEUTRAL
6-K
2/10
Chemomab Therapeutics appointed Gwen Melincoff as a new independent director and chair of the nomina
Jun 2, 2026
NEUTRAL
PRESS-RELEASE
4/10
Chemomab reported Q1 2026 net loss of $1.8M ($0.003/share) vs $3.3M in Q1 2025, with cash burn reduc
May 14, 2026
NEUTRAL
6-K
5/10
Chemomab Therapeutics reported Q1 2026 financial results, with net loss narrowing to $1.8M from $3.3
May 14, 2026
NEUTRAL
6-K
2/10
Chemomab Therapeutics filed a 6-K reporting results of its annual general meeting held on May 5, 202
May 6, 2026
Historical analyst distribution (last covering-analyst action Aug 2025): 88% buy across 8 analysts — 3 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Aug 2025. No current recommendation available.
$15.00 mean target (Aug 2025)
$5.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $1.73 |
| Target Low | $5.00 |
| Target Mean | $15.00 |
| Target Median | $15.00 |
| Target High | $25.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | 100.0% | — | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | 100.0% | +100.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.02 | $-0.02 | $-0.02 | -11.1% | +0.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-0.03 | $-0.03 | $-0.03 | -50.0% | +0.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.000 | |
| 7d ago | $0.000 | |
| 30d ago | $0.000 | |
| 60d ago | $-0.010 | +0.010 |
| 90d ago | $-0.010 | +0.010 |
5 analyst firms have rated this stock: 1 upgrades, 1 downgrades, 5 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 27, 2025 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| May 16, 2025 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Feb 20, 2025 | Maxim Group | MAINTAIN | Buy | Buy |
| Nov 15, 2024 | Oppenheimer | REITERATE | Outperform | Outperform |
| May 13, 2024 | Maxim Group | INITIATE | — | Buy |
| May 6, 2024 | Oppenheimer | UPGRADE | Perform | Outperform |
| Mar 8, 2024 | Oppenheimer | MAINTAIN | Perform | Perform |
| Oct 6, 2023 | Roth MKM | INITIATE | — | Buy |
| Jun 7, 2023 | Oppenheimer | DOWNGRADE | Outperform | Perform |
| Apr 18, 2023 | Oppenheimer | MAINTAIN | — | Outperform |
| Mar 10, 2022 | Oppenheimer | MAINTAIN | — | Outperform |
| Dec 7, 2021 | Aegis Capital | INITIATE | — | Buy |
| May 26, 2021 | Cantor Fitzgerald | INITIATE | — | Overweight |
| May 7, 2021 | Oppenheimer | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 14, 2026
earnings
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
Chemomab announced financial and operating results for the first quarter and provided a corporate update, including 4 presentations at DDW and EASL 20
May 13, 2026
earnings_calendar
CMMB Q1 2026 Earnings Scheduled — 2026-05-13
Apr 21, 2026
Clinical Trial
A Trial of Efficacy, Safety and Tolerability of LVDS (Levonorgestrel Vaginal Delivery System) During 13 Cycles
Phase Phase 3 — COMPLETED
Mar 19, 2026
earnings
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
2025 was a critical year for Chemomab and nebokitug. Partnering discussions continue to advance along with preparations to launch the PSC Phase 3 tria
Mar 2, 2026
earnings_calendar
CMMB Q4 2025 Earnings After Market Close — 2026-03-02